Latest Revenue Recognition News

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.

Blackpearl Group has reported a landmark $26.8 million in Annual Recurring Revenue (ARR) for Q4 FY26, marking a 114% year-on-year increase. With zero churn in its Data as a Service (DaaS) segment and improved customer acquisition efficiency, the company is now prioritising optimisation to accelerate cash flow and tighten customer profiles.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

SciDev Ltd trims FY26 revenue guidance to $82-$87 million from $100-$110 million due to intensified competition in Energy Services and weather-related delays at Rum Jungle, while maintaining positive EBITDA and a confident FY27 outlook.

Duratec's joint venture with Ertech has clinched a $281 million contract to upgrade submarine infrastructure at HMAS Stirling, marking a major step in Australia's AUKUS defence preparations.

Talius Group has inked a Master Services Agreement with Adventist Retirement Plus to roll out its Nurse Call and Sleep Systems across two Queensland villages, setting the stage for wider expansion and recurring revenue growth.

Charter Hall (ASX: CHC) has won a $1.2 billion diversified direct property mandate from an existing institutional client, reinforcing its growth trajectory in funds under management and showcasing its sector expertise across Australia.

Cogstate Ltd (ASX:CGS) has announced robust sales contract execution for the quarter ended 31 March 2026, with $25.4 million in new contracts and a growing revenue backlog supporting its clinical trial services business.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

Bass Oil reported steady February production with some operational setbacks in the Cooper Basin, while gaining regulatory approval for the Vanessa gas field acquisition and securing government funding for Kiwi gas development.

Cyclopharm has secured a multi-site agreement with Northwestern Medicine, marking a major expansion into Chicago’s healthcare market and reinforcing its US growth strategy.

Austal Limited has addressed ASX concerns over its half-year financial report, confirming compliance with accounting standards despite a qualified audit opinion linked to US Department of Defense contractual relief revenue.